142 related articles for article (PubMed ID: 32052132)
1. LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study.
Shropshire E; Mamidipalli A; Wolfson T; Allen BC; Jaffe TA; Igarashi S; Higaki A; Tanabe M; Gamst A; Sirlin CB; Bashir MR
Abdom Radiol (NY); 2020 Oct; 45(10):3092-3102. PubMed ID: 32052132
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
4. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?
Cannella R; Vernuccio F; Antonucci M; Gagliano DS; Matteini F; Midiri M; Brancatelli G
Eur Radiol; 2022 Mar; 32(3):1804-1812. PubMed ID: 34545444
[TBL] [Abstract][Full Text] [Related]
5. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
[TBL] [Abstract][Full Text] [Related]
6. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy.
Kim YY; Choi JY; Kim SU; Lee M; Park MS; Chung YE; Kim MJ
AJR Am J Roentgenol; 2020 Dec; 215(6):1354-1362. PubMed ID: 33052732
[No Abstract] [Full Text] [Related]
7. Effect of threshold growth as a major feature on LI-RADS categorization.
Chernyak V; Kobi M; Flusberg M; Fruitman KC; Sirlin CB
Abdom Radiol (NY); 2017 Aug; 42(8):2089-2100. PubMed ID: 28352950
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
[TBL] [Abstract][Full Text] [Related]
9. MRI LI-RADS Version 2018: Impact of and Reduction in Ancillary Features.
van der Pol CB; Dhindsa K; Shergill R; Zha N; Ferri M; Kagoma YK; Lee SY; Satkunasingham J; Wat J; Tsai S
AJR Am J Roentgenol; 2021 Apr; 216(4):935-942. PubMed ID: 33534620
[No Abstract] [Full Text] [Related]
10. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
[TBL] [Abstract][Full Text] [Related]
11. LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features.
Cerny M; Bergeron C; Billiard JS; Murphy-Lavallée J; Olivié D; Bérubé J; Fan B; Castel H; Turcotte S; Perreault P; Chagnon M; Tang A
Radiology; 2018 Jul; 288(1):118-128. PubMed ID: 29634435
[TBL] [Abstract][Full Text] [Related]
12. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
13. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.
Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W
Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759
[TBL] [Abstract][Full Text] [Related]
14. Differences in Liver Imaging and Reporting Data System Categorization Between MRI and CT.
Corwin MT; Fananapazir G; Jin M; Lamba R; Bashir MR
AJR Am J Roentgenol; 2016 Feb; 206(2):307-12. PubMed ID: 26797357
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
18. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
[TBL] [Abstract][Full Text] [Related]
19. Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging.
Chernyak V; Flusberg M; Berman J; Fruitman KC; Kobi M; Fowler KJ; Sirlin CB
Liver Transpl; 2019 Oct; 25(10):1488-1502. PubMed ID: 31344753
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
